Research
Hormonal
Adiponectin levels are inversely associated with obesity and insulin resistance, and low plasma adiponectin is a risk factor for type 2 diabetes, suggesting that boosting adiponectin could be therapeutic.
Maintaining higher levels of adiponectin is protective against diabetes. Since adiponectin levels drop with obesity, strategies that improve metabolic health (like exercise and weight loss) naturally help restore these levels. There are no approved adiponectin supplements, but lifestyle interventions that boost its activity are beneficial.
GoodSupportsHIGH confidence
Plasma adiponectin levels are decreased in type 2 diabetic patients, and higher adiponectin levels are associated with low risk of diabetes... Adiponectin levels are also negatively associated with adiposity and fasting glucose.
Why this rating
Strong observational data, but therapeutic strategies are still being explored.
Source
Adipocytokines in obesity and metabolic disease
Haiming Cao · Journal of Endocrinology · 2014
DOI 10.1530/joe-13-0339
narrative_reviewCited 707×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity induces chronic low-grade metabolic inflammation in adipose tissue, primarily through macrophage infiltration and the secretion of pro-inflammatory cytokines like TNF-alpha and IL-6, which directly causes insulin resistance and metabolic dysfunction.Strong
- Leptin resistance in obese individuals renders exogenous leptin therapy ineffective for weight loss, despite leptin's potent role in regulating energy balance and satiety.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →